Payment overview · 2025
General Payments
$412.47
17 reported records · 6 companies
Healthcare provider profile · identity verified
Luis Benjamin Gonzalez-Ingles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAYAMON, PR · NPI 1962490219
Verified facts
What the public records show
CMS Open Payments records show Luis Benjamin Gonzalez-Ingles, MD received $412.47 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 342 records involving 186 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.02 | 48.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.05 | 18.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $50.00 | 12.1% | 2 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $50.00 | 12.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.40 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.00 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.47 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.59 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $76.05 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $59.68 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 184 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 42 |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 342 supporting records · 186 recipient NPIs · example record 1186464879 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1659 | 421 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1275 | 353 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1241 | 321 |
| Metoprolol Succinate | Metoprolol Succinate | 1150 | 307 |
| Gabapentin | Gabapentin | 1127 | 263 |
| Synthroid | Levothyroxine Sodium | 832 | 187 |
| Hydrochlorothiazide | Hydrochlorothiazide | 666 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 661 | 178 |
| Glimepiride | Glimepiride | 655 | 179 |
| Metformin Hcl | Metformin Hcl | 585 | 146 |
| Alendronate Sodium | Alendronate Sodium | 571 | 166 |
| Famotidine | Famotidine | 543 | 125 |
| Pioglitazone Hcl | Pioglitazone Hcl | 492 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 132 |
| Omeprazole | Omeprazole | 437 | 103 |
| Simvastatin | Simvastatin | 400 | 101 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 329 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 85 |
| Doxazosin Mesylate | Doxazosin Mesylate | 293 | 81 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 271 | 90 |
| Montelukast Sodium | Montelukast Sodium | 271 | 83 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 265 | 68 |
| Pregabalin | Pregabalin | 260 | 73 |
| Diclofenac Potassium | Diclofenac Potassium | 258 | 82 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 257 | 77 |
| Furosemide | Furosemide | 245 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 239 | 55 |
| Nifedipine Er | Nifedipine | 232 | 73 |
| Fenofibrate | Fenofibrate | 225 | 66 |
| Xarelto | Rivaroxaban | 215 | 58 |
| Temazepam | Temazepam | 211 | 28 |
| Eliquis | Apixaban | 184 | 42 |
| Prednisone | Prednisone | 182 | 93 |
| Trazodone Hcl | Trazodone Hcl | 178 | 59 |
| Latanoprost | Latanoprost | 162 | 32 |
| Sertraline Hcl | Sertraline Hcl | 161 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 49 |
| Ezetimibe | Ezetimibe | 156 | 49 |
| Lisinopril | Lisinopril | 147 | 42 |
| Irbesartan | Irbesartan | 137 | 42 |
| Humalog | Insulin Lispro | 130 | 32 |
| Diclofenac Sodium Er | Diclofenac Sodium | 122 | 35 |
| Donepezil Hcl | Donepezil Hcl | 118 | 44 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 117 | 39 |
| Jentadueto | Linagliptin/Metformin Hcl | 115 | 24 |
| Finasteride | Finasteride | 114 | 28 |
| Glipizide | Glipizide | 114 | 24 |
| Ramipril | Ramipril | 110 | 31 |
| Carvedilol | Carvedilol | 105 | 38 |
| Levofloxacin | Levofloxacin | 104 | 93 |
| Farxiga | Dapagliflozin Propanediol | 100 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 30 |
| Meclizine Hcl | Meclizine Hcl | 94 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 25 |
| Bumetanide | Bumetanide | 83 | 29 |
| Nabumetone | Nabumetone | 81 | 21 |
| Allopurinol | Allopurinol | 79 | 22 |
| Spironolactone | Spironolactone | 79 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 24 |
| Sucralfate | Sucralfate | 77 | 32 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 71 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 24 |
| Tradjenta | Linagliptin | 69 | 13 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Lansoprazole | Lansoprazole | 67 | 11 |
| Pentoxifylline | Pentoxifylline | 67 | 16 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Jardiance | Empagliflozin | 65 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 63 | 22 |
| Enalapril Maleate | Enalapril Maleate | 63 | 21 |
| Memantine Hcl | Memantine Hcl | 63 | 26 |
| Bupropion Xl | Bupropion Hcl | 62 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 61 | 18 |
| Meloxicam | Meloxicam | 60 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 50 |
| Valsartan | Valsartan | 58 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 57 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 16 |
| Ciclopirox | Ciclopirox | 54 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 17 |
| Verapamil Er | Verapamil Hcl | 52 | 12 |
| Mometasone Furoate | Mometasone Furoate | 51 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 17 |
| Digoxin | Digoxin | 48 | suppressed |
| Entresto | Sacubitril/Valsartan | 48 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Methotrexate | Methotrexate Sodium | 47 | 11 |
| Atenolol | Atenolol | 46 | 13 |
| Etodolac Er | Etodolac | 44 | 13 |
| Flecainide Acetate | Flecainide Acetate | 44 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 44 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | 12 |
| Colchicine | Colchicine | 39 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 38 | 12 |
| Minoxidil | Minoxidil | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Methimazole | Methimazole | 35 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 33 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Cilostazol | Cilostazol | 32 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 19 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Estazolam | Estazolam | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 16 |
| Torsemide | Torsemide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Nisoldipine | Nisoldipine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.47 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, LOKELMA, MOUNJARO, REPATHA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error